

Express Mail Label No.: EV 019 224 420 US
Date of Deposit: August 2, 2002

Attorney Docket No. VPI/00-129-3 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: David Bebbington, et al.
ASSIGNEE: Vertex Pharmaceuticals Incorporated
DIVISIONAL OF: 09/952,671 EXAMINER: Thomas McKenzie
FILING DATE: HEREWITH3 ART UNIT: 1624
FOR: PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS

July 22, 2003
Cambridge, Massachusetts

MS Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being been filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97.

A copy of the references are enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the


APPLICANTS: David Bebbington, et al.
U.S.S.N.: Not Yet Assigned

cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0725, Reference No. VPI/00-129-3 DIV US.

Respectfully submitted,



Andrea L.C. Robidoux and Reg. No. 47,902
Agent for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6731
Fax: (617) 444-6483

Dated: July 22, 2003

| | | |
|---|-------------------------------|---------------------|
| Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | Application Number | Not Yet Assigned |
| | Filing Date | Herewith |
| | First Named Inventor | David Bebbington |
| | Group Art Unit | 1624 |
| | Examiner Name | Thomas McKenzie |
| | Attorney Docket Number | VPI-00-129-3 DIV US |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|-------------|-----------------------------|------------|-------------------------------------|-------|--------------|-------------------------------|
| Exam Initials | Cite No. | U.S. Patent Document No. | Issue Date | Name of Patentee(s) or Applicant(s) | Class | Sub Class | Filing Date If Appropriate |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-------------|--|--|---------------------|-----------------------|--|
| Exam Initials | Cite No. | Foreign Patent Document Office Number | Name of Patentee(s) or Applicant(s) | Date of Publication | Translation Yes No | |
| | B1* | WO 00/39101 | AstraZeneca UK Limited | 06-Jul-2000 | | |
| | B2* | WO 00/21955 | Zeneca Limited | 20-Apr-2000 | | |
| | B3* | WO 95/15758 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | 15-Jun-1995 | | |
| | | | | | | |

| OTHER NON PATENT LITERATURE DOCUMENTS | | |
|---------------------------------------|-------------|--|
| Exam Initials | Cite No. | Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc. |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. 09/952,671, filed September 14, 2001, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.